Results 91 to 100 of about 1,126 (138)

Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

, 2017
During the last decade, the development of improved and novel approaches for the treatment of hemophilia A has expanded tremendously. These approaches include factor VIII (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal ...
Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis   +2 more
core   +1 more source

Sequential Use of Recombinant Porcine Factor VIII and Early Emicizumab in Acquired Hemophilia A: A Case Series

eJHaem
Background Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder requiring prompt hemostatic control and sustained prevention of rebleeding. Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) controls acute bleeding, while emicizumab
Yusuke Yamada, Takashi Onaka, Kazunori Imada   +2 more
doaj   +1 more source

Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab provides effective prophylaxis for hemophilia A (HA), but evidence for preterm and very low-birth-weight infants remains limited. Key Clinical Question: Can emicizumab be safely initiated shortly after birth in a preterm, low-birth-
Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani   +6 more
doaj   +1 more source

Evaluation of Autoimmune FVIII Inhibitor Using Clot Waveform Analysis in Emicizumab-Treated Patients

Background/Objectives: Autoimmune factor VIII deficiency (AiFVIIID) is a rare disorder that causes severe bleeding. Emicizumab has recently been found to be effective in treating AiFVIIID; however, monitoring with standard coagulation tests presents ...
Hideo Wada, Naoki Shinke, Junichiro Nishiki, Teruto Hashiguchi, Takeshi Matsumoto, Ryota Sasao, Isao Tawara, Shigehisa Tamaki, Atsushi Fujieda   +8 more
core   +1 more source

PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience

Bleeding, Thrombosis and Vascular Biology
Background and Aims: Hemophilia A (HA) is an hereditary X-linked bleeding disorder secondary to deficiency of the clotting factor VIII (FVIII), that, if not properly treated, is associated with debilitating joint damage due to recurrent hemarthroses as ...
doaj   +1 more source

Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.

Background: Emicizumab is a bispecific antibody to factor (F) IXa and FX that mimics the FVIIIa cofactor function. Emicizumab prophylaxis markedly decreases bleeding episodes in patients with hemophilia A (PwHAs), irrespective of the presence of FVIII ...
Nogami, Keiji, Shima, Midori, Yaoi, Hiroaki, Kitazawa, Takehisa, Shida, Yasuaki   +4 more
core   +1 more source

CO-44 | EVALUATION OF THE DEVIATION BETWEEN PRESCRIBED AND RECOMMENDED EMICIZUMAB DOSING IN PATIENTS WITH CONGENITAL HEMOPHILIA A

Bleeding, Thrombosis and Vascular Biology
Background. Emicizumab, the first non-replacement therapy approved for the treatment of HA, has significantly improved patient management. However, the label-recommended dosing schedule is highly rigid and, if strictly applied, may lead to unavoidable ...
Marco Bodini
doaj  

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.

Essentials Emicizumab mimics factor (F)VIIIa cofactor function, augments the intrinsic tenase activity. We assessed the emicizumab-driven hemostatic function in FXI-deficient plasmas. Emicizumab improved the coagulation potentials in severe FXI-deficient
Minami, Hiroaki, Nogami, Keiji, Shima, Midori, Yada, Koji, Furukawa, Shoko, Ogiwara, Kenichi, Kitazawa, Takehisa, Soeda, Tetsuhiro   +7 more
core   +1 more source

Best-10 | CHANGES IN HYPERTROPHIC SYNOVIUM STATUS IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A RECEIVING EMICIZUMAB PROPHYLAXIS: THE RESOLVE STUDY

Bleeding, Thrombosis and Vascular Biology
Background. Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium, remains limited. Objectives. To evaluate changes in joint status, with a specific focus on HS, using point-of-care ultrasound and clinical examination ...
Ilenia Lorenza Calcaterra
doaj  

Emicizumab in two patients with acquired haemophilia A – case report

Patients with acquired haemophilia A (PwAHA) can present with severe bleeding and may require lengthy treatment with bypassing agents and immunosuppression. We present two cases of the implementation of emicizumab in PwAHA.
Zhao Milly, Ciolek Alana, Kartika Thomas, Snead Jessica, DeSancho Maria T, Witenko Corey   +5 more
core   +1 more source